RC108 Combine With Furmonertinib With/Without Toripalimab in Patients With EGFR-mutated NSCLC
ConditionNSCLC
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorRemeGen Co., Ltd.
About this trial
an open, single-arm, multicenter phase Ib/II study
Eligibility criteria
Qualifiers
Voluntarily agree to participate in the study and sign an informed consent form.
Age between 18 and 75 years old (inclusive).
Expected survival period of at least 12 weeks as determined by the investigator.
ECOG performance status of 0 or 1.
Disqualifiers
Have used an investigational drug within 4 weeks prior to the start of study dosing.
Have undergone major surgery within 4 weeks prior to the start of study dosing and have not fully recovered.
Received a live vaccine within 4 weeks prior to the start of study dosing or are scheduled to receive any vaccine (except novel inactivated coronavirus vaccine) during the study period.
An arterial/venous thrombotic event such as a cardiovascular accident (including temporary ischemic attack), deep vein thrombosis and pulmonary embolism within 6 months prior to study dosing.
Trial design
Treatments tested in this trial
- RC108
Treatment groups
106 Participants
are divided into 4 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov